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The early years of Ras research wit-
nessed an intense and competitive race
to discover which enzyme Ras regulates.
The discovery in 1993 that Ras binds
directly to Raf kinase suggested briefly
that the race was over. However, Ras
biology clearly differed from Raf, and the
later discovery that Ras also binds and
activates PI 3′ kinase accounted for some
of these properties. Furthermore, Ras
effectors were shown to act synergistical-
ly, implying that the full transforming
power of Ras depends on simultaneous
activation of interactive downstream
pathways. But this was just the beginning!
Ras was shown to bind to AF6/Canoe,
RalGDS, and a host of unknowns, with
binding properties as compelling as
effectors whose biology was better
known (Repasky et al., 2004). Figure 1
represents our current view of Ras sig-
naling, greatly oversimplified (Rodriguez-
Viciana et al., 2004).
How can we ever learn which of
these effector pathways is relevant to
Ras biology in vivo, and, more specifical-
ly, in human cancer?
Analysis of mutations in human
tumors gives strong clues and validates
both Raf and PI 3 kinase as crucial Ras
effectors (see below). A complimentary
approach is also proving informative:
roles of candidate downstream effectors
interrogated using knockout mice. For
example, cyclin D1 (way downstream) 
is necessary for Ras transformation
(Robles et al., 1998;Yu et al., 2001), as is
TIAM-1 (Malliri et al., 2002) and PLC-ε
(Bai et al., 2004), both possible direct
effectors.
RalGDS can now be added to the list
of biologically relevant effectors. In a
paper from the lab of long-time Ras pio-
neer Chris Marshall, González-García
and coworkers (González-García et al.,
2005) show that mice lacking RalGDS
show reduced tumor incidence, size, and
progression, in a skin cancer model in
which mutant H-ras is the primary driver.
This important discovery will direct more
attention to this pathway, including, one
hopes, a search for somatic mutations in
human cancers that put RalGDS into the
top tier of Ras effectors. Furthermore,
RalGDS and the Ral pathway, like cyclin
D1, Tiam-1, and PLC-ε, now appear to
be excellent targets for therapeutic inter-
vention, at least from a biologist’s per-
spective. Each is necessary for efficient
Ras transformation, and each is dispens-
able in normal tissue. Unfortunately,
these proteins may not be “druggable”
with current technology, but that is a
different story.
RalGDS was discovered as a Ras
partner in 1994, in two-hybrid screens
performed in the labs of Steve Martin,
Jim Bischoff, and Rusty Williams. At the
time, it was astonishing that regulation of
related small GTPases should be so
directly connected, but subsequent stud-
ies from Hans Bos, Yoshimi Takai, Larry
Feig, Mike White, Alan Hall, and many
others have established this as a central
theme in signal transduction. RalGDS is
one of several known Ras-regulated
guanine-nucleotide exchange factors, or
GEFs, that function by activating Ral A
and B GTPases (Wolthuis and Bos,
1999). Ral interacts with effectors such
as Sec5, Filamin, RalBP1, and ZONAB,
and very likely many other proteins yet to
be identified. Through these interactions,
Ral proteins regulate endocytosis, exo-
cytosis, and actin organization, and
control gene expression through tran-
scription factors such as fos, jun, AFX,
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Ras proteins send signals through multiple effector pathways. The Raf/MEK/MAPK and PI 3′ kinase pathways are well-
validated Ras effectors in human cancers, but many other candidate pathways could be equally important. RalGDS is
such a candidate: in a new paper from Chris Marshall’s group, an important role for RalGDS in Ras transformation in vivo
has been established for the first time. Mice lacking RalGDS are defective in tumor formation, possibly because of
increased apoptosis in Ras-driven tumors. The hunt for a clear role for RalGDS activation in human cancer is on.
Figure 1. Pathways downstream of Ras
Members of the Ras family bind and activate
multiple downstream effectors. Binding is
GTP-dependent and engages the highly
conserved effector binding region of Ras
and its close relatives. Direct activating
events are shown in black arrows, trasncrip-
tional events in green. This figure is greatly
oversimplified, but ilustrates the complexity
of downstream signaling and the fact that
downstream pathways are entangled at
many levels.
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and Zonab. Importantly, as suggested
before (Chien and White, 2003) and con-
firmed by González-García et al. in
mouse models in vivo, Ral may also play
a critical role in regulating survival of
tumor cells.
Caution is needed, however, when
extrapolating observations from mouse
tumor model systems to human cancer.
There is direct evidence that the contri-
bution of Ras effector pathways to cellu-
lar transformation may differ between
mouse and human cells (Hamad et al.,
2002; Rangarajan et al., 2004). Also, dif-
ferent cell types have different require-
ments for Ras effector pathways for
malignant transformation. This has been
observed in human cells in culture
(Rangarajan et al., 2004), as well as in
mouse tumor models. Cyclin D1-defi-
cient mice, for example, are totally resis-
tant to breast cancers induced by Ras,
but only impaired in Ras-induced skin
tumorigenesis (Robles et al., 1998; Yu et
al., 2001). On the other hand, MEFs
derived from cyclin D−/− mice can be fully
transformed by Ras.These differences in
cyclin D1 dependence between mouse
mammary cells, keratinocytes, and
fibroblasts may relate to the ability of Ras
to differentially induce expression of the
related cyclins D2 and D3 in a cell type-
dependant manner. Even within the
same cell type, different effectors may
also play different roles at different
stages of tumor progression. Although
Tiam1−/− mice develop fewer skin tumors
in response to Ras activation, those that
do form show enhanced progression to
malignancy (Malliri et al., 2002).
Despite these important develop-
ments, RalGDS still lacks validation as a
Ras target in human cancers. In contrast,
activating mutations in B-Raf occur fre-
quently in many human cancers, particu-
larly in melanoma. These mutations are
mutually exclusive with activating muta-
tions in N-Ras, suggesting they act in the
same pathway. Likewise, loss of PTEN
occurs frequently and is also mutually
exclusive with mutations in Ras.Together,
these data make a compelling case for a
model in which both Raf and PI kinase
pathways are activated together in the
same tumor: this can be achieved by acti-
vating Ras, or by independently activat-
ing the two pathways. However, this
model does not exclude the possible
need to activate RalGDS as well, and
potentially other Ras effectors, in tumors
with wild-type Ras. The paper from
González-García may prompt a more
intense analysis of mutations in the
RalGDS pathway in such tumors and fur-
ther analysis of the molecular basis of
synergistic interaction between Ras
effectors.
Other Ras effectors that have gained
credibility through analysis of human
tumors include Tiam-1, which appears to
be activated by mutation in some renal
cell carcinomas, and RASSF, a potential-
ly proapoptotic protein whose expression
is suppressed in human tumors. More
work is needed to establish the generali-
ty and significance of these candidates.
Activated Ras has been implicated in
many of the properties of the malignant
phenotype (i.e., uncontrolled prolifera-
tion, survival, invasion, and metastasis).
It is likely that different effector pathways
(or combinations of them) will contribute
differentially to the various aspects of
tumor biology in a cell type-dependant
manner.
The availability of knockout mice
deficient for specific Ras effectors will
greatly help unravel this seemingly end-
less complexity. Their crossing with mice
expressing active Ras under tissue-spe-
cific promoters (as well as with each
other) will allow the examination of their
specific contributions to tumorigenesis in
different tissues and during different
stages of tumor development. These
approaches will help identify effector
pathways that Ras may depend on to
cause human cancer. Analysis of muta-
tions within these pathways in human
tumor DNA will further validadte these
candidates. Ultimately, this information
could yield a deeper understanding of
Ras' role in cancer, and, hopefully, new
targets for therapeutic intervention
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